Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
Hengrui Pharma granted Novo Nordisk exclusive rights (ex-China regions) to develop and commercialize HRS-1596, with deal value up to $2.6B including a $300M upfront payment. Closing is subject to HSR clearance and other conditions, expected in Q4 2026.Material DetailsContext by AI AnalystThis is an…
Novo Nordisk entered an exclusive license with Hengrui Pharma for HRS-1596, a phase 1-ready once-weekly oral GLP-1/GIP agonist, including $300M upfront and up to $2.6B in milestones. Rights cover all markets except mainland China, Hong Kong, Macao and Taiwan.Material DetailsContext by AI AnalystThi…